Results 101 to 110 of about 286,222 (357)

Discovery of a small molecule TLR3 agonist adjuvant

open access: yesNature Communications
Pattern-recognition receptor (PRR) agonists are valuable agents across multiple medical applications, from vaccinology to immune-oncology. However, well-defined and potent small molecule agonists for many PRRs still await discovery and development ...
Branden Lee   +33 more
doaj   +1 more source

Anti-tumor activity of a T-helper 1 multiantigen vaccine in a murine model of prostate cancer [PDF]

open access: gold, 2022
Denise L. Cecil   +9 more
openalex   +1 more source

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression [PDF]

open access: yes, 2004
Tumor escape is one major obstacle that has to be addressed prior to designing and delivering successful immunotherapy. There is compelling evidence to support the notion that immunogenic tumors, in murine models and cancer patients, can be rejected by ...
Ahmad, M, Ali, SA, Rees, RC
core   +1 more source

Membrane Vesicles from Lacticaseibacillus Casei BL23 Exhibit Antimicrobial Activity Against Escherichia coli and Immunostimulatory Effects on Human Peripheral Blood Mononuclear Cells

open access: yesAdvanced Healthcare Materials, EarlyView.
Membrane vesicles derived from the probiotic Lacticaseibacillus casei BL23 demonstrate antimicrobial properties against Escherichia coli and a potential biological effect in improving the overall survival of C. elegans infected with Pseudomonas aeruginosa. These vesicles stimulated immune responses in primary cells without causing toxicity. Our results
Cecilia L. D'Antoni   +11 more
wiley   +1 more source

Immune profiling of age and adjuvant-specific activation of human blood mononuclear cells in vitro

open access: yesCommunications Biology
Vaccination reduces morbidity and mortality due to infections, but efficacy may be limited due to distinct immunogenicity at the extremes of age. This raises the possibility of employing adjuvants to enhance immunogenicity and protection.
Simone S. Schüller   +7 more
doaj   +1 more source

Microphysiological Systems of Lymphatics and Immune Organs

open access: yesAdvanced Healthcare Materials, EarlyView.
This review surveys recent progress in engineering lymphatic microenvironments and immune organoids within microphysiological systems, emphasizing innovative strategies to recreate the biochemical and biophysical complexity of native lymphatic tissues.
Ishita Jain   +2 more
wiley   +1 more source

Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein

open access: yesJournal of Virology
An estimated 10–20 million people worldwide are infected with the deltaretrovirus human T-cell leukemia virus type 1 (HTLV-1). Although most infected individuals remain asymptomatic, some progress to develop the fatal and debilitating disease adult T ...
Cynthia A. Pise-Masison   +11 more
doaj   +1 more source

Strategies to Improve the Lipophilicity of Hydrophilic Macromolecular Drugs

open access: yesAdvanced Healthcare Materials, EarlyView.
Hydrophilic macromolecular drugs can be successfully lipidized by covalent attachment of lipids, by hydrophobic ion pairing with negatively or positively charged surfactants, and by dry or wet reverse micelle formation. Lipophilicity enhancement of hydrophilic macromolecules has several benefits including stability and bioavailability improvement ...
Sera Lindner   +8 more
wiley   +1 more source

Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]

open access: yes, 2014
Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin   +9 more
core   +2 more sources

Evaluating the Antiviral Efficacy of Encapsulated PKC Inhibitor BIM‐I against influenza A Virus Infection

open access: yesAdvanced Healthcare Materials, EarlyView.
This study explores nanoparticle delivery of the protein kinase C inhibitor bisindolylmaleimide‐I (BIM‐I) to combat influenza A virus infections. Encapsulation in biodegradable PLGA nanoparticles improved safety while maintaining the compound's strong antiviral activity.
Laura Klement   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy